10x Genomics, Inc. (BMV:TXG)
| Market Cap | 129.84B +257.3% |
| Revenue (ttm) | 11.15B -3.6% |
| Net Income | -1.21B |
| EPS | -9.97 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1,215.62 |
| Previous Close | 1,215.62 |
| Day's Range | 1,215.62 - 1,215.62 |
| 52-Week Range | 270.00 - 1,623.32 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About 10x Genomics
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p... [Read more]
Financial Performance
In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.
Financial numbers in USD Financial StatementsNews
ACHR, LUNR, TXG: Cathie Wood Sells $6.1M of One Growth Stock, Buys the Other Two
Cathie Wood’s ARK Invest sold 107,658 shares of 10x Genomics ($TXG) on Tuesday, November 17. According to ARK’s daily fund disclosures, the firm accumulated additional shares in two other growth stock...
10x Genomics Transcript: Jefferies Global Healthcare Conference
Atera demand exceeded expectations and supply, with interest reaching beyond existing Xenium users and planned production scaling from Q1. Single-cell pricing transition is expected to continue for another couple of quarters, while spatial AI and clinical applications advance.
10x Genomics announces two new research collaborations
10x Genomics (TXG) announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease. The first collaboration is...
10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations
Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform PLEASANTON, Calif., Nov. ...
Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), ...
10x Genomics price target lowered to $65 from $70 at JPMorgan
JPMorgan lowered the firm’s price target on 10x Genomics (TXG) to $65 from $70 and keeps a Neutral rating on the shares.
10x Genomics price target lowered to $65 from $80 at BofA
BofA lowered the firm’s price target on 10x Genomics (TXG) to $65 from $80 and keeps a Neutral rating on the shares. The firm says the company’s showed progress ahead…
10x Genomics price target lowered to $61 from $90 at UBS
UBS analyst Doug Schenkel lowered the firm’s price target on 10x Genomics (TXG) to $61 from $90 and keeps a Neutral rating on the shares.
10x Genomics price target lowered to $55 from $70 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $55 from $70 and keeps a Hold rating on the shares.The firm updated its model…
10x Genomics price target lowered to $61 from $90 at UBS
UBS lowered the firm’s price target on 10x Genomics (TXG) to $61 from $90 and keeps a Neutral rating on the shares. 10x Genomics delivered largely in-line results with upside…
10x Genomics price target raised to $68 from $50 at Stifel
Stifel raised the firm’s price target on 10x Genomics (TXG) to $68 from $50 and keeps a Buy rating on the shares.
10x Genomics price target raised to $60 from $50 at Citi
Citi raised the firm’s price target on 10x Genomics (TXG) to $60 from $50 and keeps a Neutral rating on the shares.
10x Genomics price target lowered to $70 from $110 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $70 from $110 and keeps an Overweight rating on the shares. The firm updated the company’s…
10x Genomics reports Q3 EPS (15c) vs. (22c) last year
Reports Q3 revenue $150.7M, consensus $147.85M. Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026. “The biggest highlight of the quarter was the start…
10x Genomics raises 2026 revenue view to $625M-$635M from $610M-$630M
2026 revenue consensus $620.58M.
10x Genomics Earnings Call Transcript: Q3 2026
Q3 revenue rose 1% YoY, with consumables growth and 16% spatial consumables growth. Strong Atera demand drove higher FY26 guidance, while manufacturing and installation capacity constrain the ramp and weigh on near-term margins.
10x Genomics Earnings release: Q3 2026
10x Genomics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
10x Genomics Prepared remarks: Q3 2026
10x Genomics filed a regulatory document on November 5, 2026 disclosing important business information.
10x Genomics Quarterly report: Q3 2026
10x Genomics has published its Q3 2026 quarterly earnings report on November 5, 2026.
10x Genomics Reports Third Quarter 2026 Financial Results
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financi...
10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
Powered by Anthropic's Claude, Sentira Single Cell enables researchers to analyze Chromium data using natural language, accelerating the path from scientific questions to experimental conclusions PLEA...
10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced today that ...
10x Genomics downgraded to Equal Weight from Overweight at Stephens
Stephens downgraded 10x Genomics (TXG) to Equal Weight from Overweight with an unchanged price target of $65.
Stephens downgrades Illumina and 10x Genomics following outperformance
As previously reported, Stephens analyst Mason Carrico downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213, and 10x Genomics (TXG) to Equal…
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will rep...